Asclea closes Series A funding led by IBB Ventures consortium, adds Quercus, Catalpa Ventures

• IBB Ventures led a Series A round at Berlin-based Ascléa, formerly x-cardiac, alongside business angels.
• Quercus and Catalpa Ventures joined the investor group; the company did not disclose the amount raised.
• Ascléa develops Clé, a platform for hospitals to run language models and agentic AI under sovereign control on-premise or via European providers.
• Proceeds will fund product development as Ascléa expands beyond cardiac-surgery risk prediction into broader clinical AI workflows.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBB Capital GmbH published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.